BOSTON

波士顿

,

，

Sept. 9, 2026

2026年9月9日

/PRNewswire/ --

/美通社/ --

PostEra

PostEra

, a biotechnology company specializing in artificial intelligence for small molecule drug discovery and reproductive endocrinology, today announced that EMD Serono, Inc., the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, has acquired two of PostEra's programs directed at fertility indications..

，一家专注于利用人工智能进行小分子药物发现和生殖内分泌学的生物技术公司，今日宣布，德国达姆施塔特默克集团（Merck KGaA, Darmstadt, Germany）旗下负责美国和加拿大医疗保健业务的EMD Serono, Inc.已收购PostEra的两个针对生育适应症的项目。

Over the last 2 years PostEra has used its AI platform,

在过去两年中，PostEra 利用其人工智能平台，

Proton

质子

, to develop novel small molecule treatments in Women's Health and Fertility; large markets almost entirely dependent on injectable medications, with unmet needs around patient convenience that need to be addressed by today's biopharma industry.

，以开发用于女性健康和生育领域的新型小分子疗法；这些市场规模庞大，但几乎完全依赖注射类药物，存在围绕患者便利性的未满足需求，亟需当今的生物制药行业加以解决。

Within Fertility, Proton was used to develop a series of novel Follicle-Stimulating Hormone Receptor (FSHR) agonists for ovarian stimulation in IVF. In parallel, PostEra also developed novel small molecule agonists of the Luteinizing Hormone/Choriogonadotropin Receptor (LHCGR) for male infertility and ovulation trigger in IVF.

在生育领域，Proton 被用于开发一系列新型卵泡刺激素受体（FSHR）激动剂，用于体外受精（IVF）中的卵巢刺激。与此同时，PostEra 还开发了新型黄体生成素/绒毛膜促性腺激素受体（LHCGR）小分子激动剂，用于治疗男性不育症以及作为体外受精（IVF）中的排卵触发药物。

Standalone, the LHCGR agonist has shown the potential in preclinical studies to offer an oral alternative to injectable hCG regimens used for selected male infertility patients. A combination of the FSHR and the LHCGR agonists could potentially transform the current IVF protocol from injections to an all-oral regimen; a step-change in treatment for women undergoing IVF..

单独使用时，LHCGR激动剂在临床前研究中已显示出潜力，可为特定男性不育症患者提供口服替代方案，以取代注射用hCG方案。FSHR激动剂与LHCGR激动剂联合使用，有望将当前的体外受精（IVF）方案从注射给药转变为全口服给药，从而为接受IVF治疗的女性带来治疗方式的根本性变革。

EMD Serono has acquired PostEra's FSHR and LHCGR agonist programs. Following completion of the transaction, EMD Serono will assume sole responsibility for the continued development and potential commercialization of the programs worldwide. Both programs are currently in preclinical development, and their safety and efficacy in humans have not been established..

EMD Serono 已收购 PostEra 的 FSHR 和 LHCGR 激动剂项目。交易完成后，EMD Serono 将独自负责这些项目在全球范围内的持续开发和潜在商业化。目前，这两个项目均处于临床前开发阶段，其在人体中的安全性和有效性尚未确立。

'We view this transaction as validation of both the very real opportunity in Women's Health and reproductive endocrinology and also of the strength of our

“我们将此次交易视为对女性健康与生殖内分泌学领域切实存在的机遇，以及我们实力的双重验证。”

Proton

质子

platform in delivering high quality clinical candidates against challenging targets. Both FSHR and LHCGR are targets which have been validated by biologics, but over the past few decades there has been little progress in drugging them with orally bioavailable small molecules. Our work in FSHR and LHCGR is a clear benchmark of how the .

该平台在针对挑战性靶点提供高质量临床候选药物方面表现出色。FSHR和LHCGR均是经生物制剂验证的靶点，但在过去几十年中，在开发具有口服生物利用度的小分子药物方面进展甚微。我们在FSHR和LHCGR方面的研究清晰地展示了如何

Proton

质子

platform can move the needle in challenging medicinal chemistry, and unlock a new era in fertility treatments.', said Dr. Lee, PostEra's Chief Scientific Officer.

“该平台能够在具有挑战性的药物化学领域取得显著进展，并开启生育治疗的新纪元。”PostEra首席科学官李博士表示。

'Our AI benchmark at PostEra has always been high quality chemical matter. We judge ourselves not simply on whether we can beat a metric, or top a leaderboard, but can we actually develop promising novel therapies that have the potential to help human health. For our Fertility pipeline, we are so pleased that EMD Serono, Inc.

在PostEra，我们的AI基准始终是高质量的化学物质。我们评判自身的标准，并不仅仅在于能否超越某项指标或登顶排行榜，而在于我们是否真正能够开发出具有潜力改善人类健康的有前景的新型疗法。针对我们的生育管线，我们非常高兴能与EMD Serono, Inc.

a globally-recognized player in this space will take these programs forward', added Aaron Morris, PostEra's Chief Executive Officer..

“这一领域内一家全球公认的领先企业将推动这些项目向前发展，”PostEra 首席执行官 Aaron Morris 补充道。

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示